Enterprise Value

149.6M

Cash

355.6M

Avg Qtr Burn

-46.35M

Short % of Float

18.89%

Insider Ownership

1.15%

Institutional Own.

65.88%

Qtr Updated

03/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
INPEFA™ (SOTAGLIFLOZIN) Details
Heart disease, Heart failure

Approved

Quarterly sales

XERMELO® (telotristat ethyl) Details
Carcinoid syndrome diarrhea

Approved

Quarterly sales

NDA

Submission

Phase 3

Initiation

LX9211 Details
Diabetic peripheral neuropathy, Neuropathy

Phase 2b

Data readout